Marcus Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Marcus Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$622K	Sell	23,350 -550	-2%	-$18K	1.81%	26
2018 Q2	$903K	Buy	23,900 +950	+4%	+$36.3K	2.87%	12
2018 Q1	$750K	Buy	22,950 +7,325	+47%	+$321K	2.76%	13
2017 Q4	$761K	Sell	15,625 -36,725	-70%	-$1.86M	2.91%	14
2017 Q3	$2.83M	Sell	52,350 -18,250	-26%	-$1.07M	4.02%	5
2017 Q2	$3.97M	Sell	70,600 -27,075	-28%	-$1.08M	3.4%	4
2017 Q1	$3.83M	Buy	97,675 +4,975	+5%	+$158K	3.57%	4
2016 Q4	$2.08M	Buy	92,700 +11,000	+13%	+$215K	2.24%	21
2016 Q3	$1.85M	Buy	81,700 +6,550	+9%	+$154K	1.78%	27
2016 Q2	$1.77M	Buy	75,150 +2,125	+3%	+$52.5K	1.87%	26
2016 Q1	$1.49M	Buy	73,025 +18,000	+33%	+$571K	1.64%	28
2015 Q4	$2.83M	Buy	+55,025	New	+$2.67M	3.01%	12

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marcus Capital's PTLA Position: Q3 2018 in Review

Marcus Capital reduced its Portola Pharmaceuticals, Inc. (PTLA) stake by 2.3% in Q3 2018, selling an estimated $18K and leaving 23,350 shares worth $622K. The position accounts for 1.81% of the portfolio, ranked #26.

Marcus Capital first reported a position in PTLA in Q4 2015 and has held it in 12 quarters since. The position peaked at $3.97M in Q2 2017. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

Marcus Capital held 23,350 shares of Portola Pharmaceuticals, Inc. worth $622K as of Q3 2018.
Marcus Capital sold 550 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $18K.
Portola Pharmaceuticals, Inc. made up 1.81% of Marcus Capital's portfolio in Q3 2018, its #26 holding.
Marcus Capital first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and has held it in 12 quarters since.
Marcus Capital's Portola Pharmaceuticals, Inc. position peaked at $3.97M in Q2 2017.
197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Marcus Capital's 13F filing for Q3 2018, filed 13 Nov 2018.